Drug Development
On Friday, the FDA approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.
FEATURED STORIES
Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.
Idorsia is no longer continuing research into the use of ACT-539313 to treat binge eating disorders after failing to meet the primary endpoint in its latest trial.
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.
Orion announced that it will be focusing on pain and oncology going forward. As a result, 32 working professionals within the company will be terminated, although six of those will be offered different positions.
Oxurion NV’s proposed drug for diabetic macular edema failed to demonstrate efficacy on key endpoints based on top line results from its Phase II trial.
LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.